Hospital Acquired Infection Treatment Market (Infection Type - Urinary Tract Infections, Ventilator Associated Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infection, ENT Infections, Skin Infection, and Bone Infection; Treatment Type - Antibacterial, Antiviral, Antifungal Treatment, Antiparasitic, Antiprotozoal, and Anti-TB Treatment; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Store, and E-Commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2030
Published Date
No. of Pages
Description
Hospital Acquired Infection Treatment Market Rides on Increased Prevalence of HAI Worldwide
A hospital-acquired infection (HAI) is also otherwise known as a nosocomial infection. It is a type of infection that is contacted in a healthcare facility or in a hospital. The infection is also known as health care–associated infection in an effort to emphasize on both non-hospital and hospital settings. A rise in the incidences of such an infection is expected to give a boost to the global hospital acquired infection treatment market over the timeframe of projection.
Fungal, bacterial, and viral pathogens cause hospital-acquired infections. The most common types are surgical site infection (SSI), urinary tract infection (UTI), pneumonia (such as ventilator-associated pneumonia), and bloodstream infection (BSI).
Market Growth to be driven by Vulnerability of Newborn Babies toward HAI
In some cases, hospital acquired infection manifests itself weeks after discharge from the hospital though it had been contacted in the hospital. The infection could also infect the hospital staff and caregivers associated with taking care of such patients. Such high prevalence and contagiousness of the infection is likely to spell growth for the global hospital acquired infection treatment market in near future.
Many antimicrobial drugs have proven to be highly effective in treating a wide range of hospital-related infections that are highly prevalent across the globe. Treatments of hospital-acquired infections comprise the following
- Antifungal therapy
- Antiviral therapy
The most sterilized sections of the hospital are the neonatal intensive care units (NICUs), which keeps infants as they are more vulnerable to such infections during the span of their hospital stay. The National Institute of Child Health and Human Development (NICHD) conducted a study titled “Neonatal Network”. The study projected that around 29% of the infants born at 25 to 28 weeks of gestation period and 46% of the newborns born at less than 25 weeks of gestation are estimated to experience severe hospital acquired infection over the period of hospitalization at NICU. High vulnerability of infants likely to play an important role in the development of the global hospital acquired infection treatment market in near future.
The global hospital acquired infection treatment (HAI) market for the historical period 2017–2018 and forecast period 2019–2027, unhygienic conditions and improper sterilization treatment, lack of surveillance systems for HAIs, high susceptibility of neonatal population, and rising geriatric population are projected to drive the global hospital acquired infection treatment (HAI) market during the forecast period
According to the report, the global hospital acquired infection treatment (HAI) market was valued at US$ 31.0 Bn in 2018 and is anticipated to expand at a CAGR of 2.5% from 2019 to 2027
fa global hospital acquired infection treatment market
To know the scope of our report Get a Sample on Hospital Acquired Infection Treatment Market
Rising Geriatric Population and Unhygienic Conditions and Improper Sterilization Treatment: Key Drivers
Continuous increase in the geriatric population is expected to be one of the potential drivers of the hospital acquired infection (HAI) treatment market during the forecast period. The geriatric population is at high risk of infection due to the age-related immunity decline, known as immunosenescence. Moreover, such patients required more time to heal and hospital stay to get recovered.
Increase in need for effective antibacterial treatment options for the geriatric population is expected to drive the demand for the hospital acquired infection treatment (HAI) market
According to WHO estimates, the global geriatric population is likely to reach around 2 billion (22% of global population) by 2050, which is currently 566 million.
Hospital acquired infections are one the highly frequent adverse events in the health care industry. Presence of unhygienic conditions around and inside the hospital along with improper sterilization techniques applied in the hospitals are increasing the prevalence of hospital acquired infection in low income and middle income countries.
According to an article published by Global Antibiotic Resistance Partnership (GARP), more than 190,000 neonatal deaths occurred in India annually due to infection
Get a glimpse of the in-depth analysis through our Report Brochure
Lack of Surveillance Systems for HAIs Boost Market Growth
Increasing prevalence of HAIs is because most countries do not have surveillance systems for HAIs, while the countries that have the systems in place often face difficulties with the complexity and lack of standardized criteria for diagnosing the infections. Countries in North America and Europe have surveillance systems for HAI monitoring while countries in Asia Pacific and rest of the world do not have the systems, which makes it difficult to control the outbreak of endemics in these regions.
The Healthcare-Associated Infections Surveillance Network (HAI-Net), National Healthcare Safety Network (NHSN), and Japan Nosocomial Infection Surveillance System (JANIS) are some of the surveillance systems working efficiently in developed countries
Multi-drug Resistant Bacteria Making Presently Available Antibacterial Drugs Outdated to Hamper Market
Multi-drug resistance is one of the most common causes of failure in treatment for bacterial infection. Bacteria are the only species that can survive even after frequent exposure to one or more antibiotics and develop drug resistance.
Moreover, these infections result in higher rate of disability and death compared to the infections that are easily treatable with antibiotics. Multi-drug resistance is affecting the HAI treatment market due to the shift of treatment process.
Major types of multi-drug resistant bacteria are methicillin resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), and multidrug-resistant Mycobacterium tuberculosis (MDR-TB).
Global Hospital Acquired Infection Treatment (HAI) Market: Competitive Landscape
This report profiles major players in the global hospital acquired infection treatment (HAI) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global hospital acquired infection treatment (HAI) market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global hospital acquired infection treatment (HAI) market
- Abbott Laboratories
- Pfizer, Inc.
- Bayer AG
- AstraZeneca
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Cipla Inc.
- GlaxoSmithKline plc
- Aridis Pharmaceuticals, Inc
- Astellas Pharma Inc.
- Daiichi Sankyo, Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company among others.
Key Questions Answered in Global Hospital acquired infection treatment (HAI) Market Report
- What is the scope of growth of product companies in the global hospital acquired infection treatment (HAI) market?
- What will be the Y-o-Y growth of the global hospital acquired infection treatment (HAI) market between 2019 and 2027?
- What is the influence of changing trends in technologies on the global hospital acquired infection treatment (HAI) market?
- Will North America continue to be the most profitable market for hospital acquired infection treatment (HAI) providers?
- Which factors are anticipated to hamper the growth of the global hospital acquired infection treatment (HAI) market during the forecast period?
- Which are the leading companies in the global hospital acquired infection treatment (HAI) market?
Global Hospital acquired infection treatment (HAI) Market - Segmentation
Infection Type
- Urinary Tract Infection
- Ventilator-Associated Pneumonia
- Bloodstream Infection
- Surgical Site Infection
- Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)
Treatment
- Antibacterial Treatment
- Beta-Lactams
- Quinolones
- Vancomycin
- Other
- Antiviral Treatment
- Acyclovir
- Foscarnet
- Antifungal Treatment
- Amphotericin B
- Triazoles
- Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
- E-Commerce
- Other
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
TABLE OF CONTENT
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Hospital Acquired Infection Treatment (HAI) Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, 2017–2030
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Guidelines for Hospital Acquired Infection Treatment
5.2. Epidemiology of Hospital Acquired Infection, By Key Countries
5.3. Regulations for Controlling Hospital Acquired Infection, By Region
5.4. Future Market Outlook
6. Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Infection Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Infection Type, 2017–2030
6.3.1. Urinary Tract Infection
6.3.2. Ventilator-Associated Pneumonia
6.3.3. Bloodstream Infection
6.3.4. Surgical Site Infection
6.3.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)
6.4. Market Attractiveness By Infection Type
7. Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Treatment
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Treatment, 2017–2030
7.3.1. Antibacterial Treatment
7.3.1.1. Beta-Lactams
7.3.1.2. Quinolones
7.3.1.3. Vancomycin
7.3.1.4. Other
7.3.2. Antiviral Treatment
7.3.2.1. Acyclovir
7.3.2.2. Foscarnet
7.3.3. Antifungal Treatment
7.3.3.1. Amphotericin B
7.3.3.2. Triazoles
7.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)
7.4. Market Attractiveness By Treatment
8. Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2017–2030
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Drug Store
8.3.4. E-Commerce
8.3.5. Other
8.4. Market Attractiveness By Distribution Channel
9. Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Region
10. North America Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast By Infection Type, 2017–2030
10.2.1. Urinary Tract Infection
10.2.2. Ventilator-Associated Pneumonia
10.2.3. Bloodstream Infection
10.2.4. Surgical Site Infection
10.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)
10.3. Market Value Forecast By Treatment, 2017–2030
10.3.1. Antibacterial Treatment
10.3.1.1. Beta-Lactams
10.3.1.2. Quinolones
10.3.1.3. Vancomycin
10.3.1.4. Other
10.3.2. Antiviral Treatment
10.3.2.1. Acyclovir
10.3.2.2. Foscarnet
10.3.3. Antifungal Treatment
10.3.3.1. Amphotericin B
10.3.3.2. Triazoles
10.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)
10.4. Market Value Forecast By Distribution Channel, 2017–2030
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Drug Store
10.4.4. E-Commerce
10.4.5. Other
10.5. Market Value Forecast By Country, 2017–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Infection Type
10.6.2. By Treatment
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast By Infection Type, 2017–2030
11.2.1. Urinary Tract Infection
11.2.2. Ventilator-Associated Pneumonia
11.2.3. Bloodstream Infection
11.2.4. Surgical Site Infection
11.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)
11.3. Market Value Forecast By Treatment, 2017–2030
11.3.1. Antibacterial Treatment
11.3.1.1. Beta-Lactams
11.3.1.2. Quinolones
11.3.1.3. Vancomycin
11.3.1.4. Other
11.3.2. Antiviral Treatment
11.3.2.1. Acyclovir
11.3.2.2. Foscarnet
11.3.3. Antifungal Treatment
11.3.3.1. Amphotericin B
11.3.3.2. Triazoles
11.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)
11.4. Market Value Forecast By Distribution Channel, 2017–2030
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Drug Store
11.4.4. E-Commerce
11.4.5. Other
11.5. Market Value Forecast By Country, 2017–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Infection Type
11.6.2. By Treatment
11.6.3. By Distribution Channel
11.6.4. By Country
12. Asia Pacific Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast By Infection Type, 2017–2030
12.2.1. Urinary Tract Infection
12.2.2. Ventilator-Associated Pneumonia
12.2.3. Bloodstream Infection
12.2.4. Surgical Site Infection
12.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)
12.3. Market Value Forecast By Treatment, 2017–2030
12.3.1. Antibacterial Treatment
12.3.1.1. Beta-Lactams
12.3.1.2. Quinolones
12.3.1.3. Vancomycin
12.3.1.4. Other
12.3.2. Antiviral Treatment
12.3.2.1. Acyclovir
12.3.2.2. Foscarnet
12.3.3. Antifungal Treatment
12.3.3.1. Amphotericin B
12.3.3.2. Triazoles
12.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)
12.4. Market Value Forecast By Distribution Channel, 2017–2030
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Drug Store
12.4.4. E-Commerce
12.4.5. Other
12.5. Market Value Forecast By Country, 2017–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Infection Type
12.6.2. By Treatment
12.6.3. By Distribution Channel
12.6.4. By Country
13. Latin America Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast By Infection Type, 2017–2030
13.2.1. Urinary Tract Infection
13.2.2. Ventilator-Associated Pneumonia
13.2.3. Bloodstream Infection
13.2.4. Surgical Site Infection
13.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)
13.3. Market Value Forecast By Treatment, 2017–2030
13.3.1. Antibacterial Treatment
13.3.1.1. Beta-Lactams
13.3.1.2. Quinolones
13.3.1.3. Vancomycin
13.3.1.4. Other
13.3.2. Antiviral Treatment
13.3.2.1. Acyclovir
13.3.2.2. Foscarnet
13.3.3. Antifungal Treatment
13.3.3.1. Amphotericin B
13.3.3.2. Triazoles
13.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)
13.4. Market Value Forecast By Distribution Channel, 2017–2030
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Drug Store
13.4.4. E-Commerce
13.4.5. Other
13.5. Market Value Forecast By Country, 2017–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Infection Type
13.6.2. By Treatment
13.6.3. By Distribution Channel
13.6.4. By Country
14. Middle East & Africa Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast
14.1. Introduction
14.2. Market Value Forecast By Infection Type, 2017–2030
14.2.1. Urinary Tract Infection
14.2.2. Ventilator-Associated Pneumonia
14.2.3. Bloodstream Infection
14.2.4. Surgical Site Infection
14.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)
14.3. Market Value Forecast By Treatment, 2017–2030
14.3.1. Antibacterial Treatment
14.3.1.1. Beta-Lactams
14.3.1.2. Quinolones
14.3.1.3. Vancomycin
14.3.1.4. Other
14.3.2. Antiviral Treatment
14.3.2.1. Acyclovir
14.3.2.2. Foscarnet
14.3.3. Antifungal Treatment
14.3.3.1. Amphotericin B
14.3.3.2. Triazoles
14.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)
14.4. Market Value Forecast By Distribution Channel, 2017–2030
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Drug Store
14.4.4. E-Commerce
14.4.5. Other
14.5. Market Value Forecast By Country, 2017–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Infection Type
14.6.2. By Treatment
14.6.3. By Distribution Channel
14.6.4. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2018)
15.3. Company Profiles
15.3.1. Abbott Laboratories
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Pfizer Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Bayer AG
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Cepheid, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. AstraZeneca plc
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. F. Hoffmann-La Roche Ltd
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Johnson & Johnson Services, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Merck & Co., Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Cipla Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. GlaxoSmithKline plc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Company Financials
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis
15.3.11. Aridis Pharmaceuticals, Inc.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Company Financials
15.3.11.3. Growth Strategies
15.3.11.4. SWOT Analysis
15.3.12. Astellas Pharma Inc.
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Company Financials
15.3.12.3. Growth Strategies
15.3.12.4. SWOT Analysis
15.3.13. Daiichi Sankyo, Inc.
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Company Financials
15.3.13.3. Growth Strategies
15.3.13.4. SWOT Analysis
15.3.14. Bristol-Myers Squibb Company
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Company Financials
15.3.14.3. Growth Strategies
15.3.14.4. SWOT Analysis
15.3.15. Eli Lilly and Company
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Company Financials
15.3.15.3. Growth Strategies
15.3.15.4. SWOT Analysis